专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CZ2003151A3 Serine protease NS3 peptide inhibitors and pharmaceutical preparation 未知
公开(公告)号：CZ2003151A3
公开(公告)日：2003-05-14
申请号：CZ2003151
申请日：2001-07-19
申请人： SCHERING CORP , CORVAS INTERNATIONAL
发明人： MCCORMICK JINPING L , WANG HAIYAN , PIKE RUSSELL E , BOGEN STEPHANE L , CHAN TIN YAU , LIU YI-TSUNG , ZHU ZHAONING , NJOROGE F GEORGE , ARASAPPAN ASHOK , PAREKH TEJAL N , GANGULY ASHIT K , CHEN KEVIN X , VENKATRAMAN SRIKANTH , VACCARO HENRY A , PINTO PATRICK A , SANTHANAM BAMA , WU WANLI , HENDRATA SISKA , HUANG YUHUA , KEMP SCOTT JEFFREY , LEVY ODILE ESTHER , LIM-WILBY MARGUERITA , TAMURA SUSAN Y , SAKSENA ANIL K , GIRIJAVALLABHAN VIYYOOR MOOPIL , LOVEY RAYMOND G , JAO EDWIN E , BENNETT FRANK
IPC分类号： A61K45/00 , A61K31/7056 , A61K38/00 , A61K38/08 , A61K38/21 , A61P31/14 , A61P43/00 , C07K5/02 , C07K5/08 , C07K5/087 , C07K7/02 , C07K5/10 , A61K38/07 , A61K38/06 , A61P31/00
摘要： The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

3. 发明专利

HU0303358A2 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 未知
公开(公告)号：HU0303358A2
公开(公告)日：2004-01-28
申请号：HU0303358
申请日：2001-07-19
申请人： CORVAS INTERNATIONAL , SCHERING CORP
发明人： ARASAPPAN ASHOK , BENNETT FRANK , BOGEN STEPHANE L , CHAN TIN-YAU , CHEN KEVIN X , GANGULY ASHIT K , GIRIJAVALLABHAN VIYYOOR MOOPIL , JAO EDWIN E , KEMP SCOTT JEFFREY , LEVY ODILE ESTHER , LIM-WILBY MARGUERITA , LIU YI-TSUNG , LOVEY RAYMOND G , MCCORMICK JINPING L , NJOROGE F GEORGE , PAREKH TEJAL N , PIKE RUSSELL E , PINTO PATRICK A , SAKSENA ANIL K , SANTHANAM BAMA , TAMURA SUSAN Y , VACCARO HENRY A , VENKATRAMAN SRIKANTH , WANG HAIYAN , ZHU ZHAONING
IPC分类号： C12N9/99 , A61K31/16 , A61K31/195 , A61K31/27 , A61K31/357 , A61K31/385 , A61K31/403 , A61K31/4164 , A61K31/445 , A61K31/7052 , A61K38/00 , A61K38/05 , A61K38/21 , A61K38/55 , A61K45/00 , A61P1/16 , A61P31/12 , A61P31/14 , A61P43/00 , C07C205/51 , C07C229/00 , C07D209/02 , C07K5/02 , C07K5/103 , C07K7/02 , C07K7/04 , C07K7/06
摘要： The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

4. 发明申请

WO0177113A3 MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES 审中-公开
标题翻译：丙型肝炎病毒NS3-丝氨酸蛋白酶抑制剂包含N-环磷酸酯酶的乙型肝炎病毒
公开(公告)号：WO0177113A3
公开(公告)日：2002-06-20
申请号：PCT/US0110869
申请日：2001-04-03
申请人： SCHERING CORP
发明人： CHEN KEVIN X , ARASAPPAN ASHOK , VENKATRAMAN SRIKANTH , PAREKH TEJAL N , GU HAINING , NJOROGE F GEORGE , GIRIJAVALLABHAN VIYYOOR M , GANGULY ASHIT , SAKSENA ANIL , JAO EDWIN , YAO NANHUA H , PRONGAY ANDREW J , MADISON VINCENT S , VIBULBHAN BANCHA
IPC分类号： C12N9/99 , A61K31/7052 , A61K38/00 , A61K38/21 , A61K38/55 , A61K45/00 , A61P31/12 , A61P31/14 , A61P43/00 , C07K1/02 , C07K5/023 , C07K5/08 , C07K5/083 , C07K5/12 , C07K7/02 , C07K7/06 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/08 , C07K5/062 , C07K5/065 , C07K5/087 , C07K5/107 , C07K14/18
CPC分类号： C07K5/12 , A61K38/00 , C07K1/02 , C07K5/08 , C07K5/0802 , C07K5/0806 , C07K7/02
摘要： The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such macrocycles as well as methods of using them to treat disorders associated with the HCV protease.
摘要翻译：本发明公开了具有HCV蛋白酶抑制活性的新型大环化合物及其制备方法。在另一个实施方案中，本发明公开了包含这种大环化合物的药物组合物以及使用它们治疗与HCV蛋白酶相关的病症的方法。

5. 发明专利

JP2009292832A New peptide as ns3-serine protease inhibitor of hepatitis c virus 审中-公开
标题翻译：新型肽作为丙型肝炎病毒的NS3-丝氨酸蛋白酶抑制剂
公开(公告)号：JP2009292832A
公开(公告)日：2009-12-17
申请号：JP2009183355
申请日：2009-08-06
申请人： Dendreon Corp , Schering Corp , シェーリングコーポレイションSchering Corporation , デンドレオンコーポレイション
发明人： SAKSENA ANIL K , GIRIJAVALLABHAN VIYYOOR MOOPIL , BOGEN STEPHANE L , LOVEY RAYMOND G , JAO EDWIN E , BENNETT FRANK , MCCORMICK JINPING L , WANG HAIYAN , PIKE RUSSELL E , LIU YI-TSUNG , CHAN TIN-YAU , ZHU ZHAONING , ARASAPPAN ASHOK , CHEN KEVIN X , VENKATRAMAN SRIKANTH , PAREKH TEJAL N , PINTO PATRICK A , SANTHANAM BAMA , NJOROGE F GEORGE , GANGULY ASHIT K , VACCARO HENRY A , SCOTT JEFFREY KEMP , ODILE ESTHER LEVY , LIM-WILBY MARGUERITA , TAMURA SUSAN Y
IPC分类号： C07K7/06 , C12N9/99 , A61K31/16 , A61K31/195 , A61K31/27 , A61K31/357 , A61K31/385 , A61K31/403 , A61K31/4164 , A61K31/445 , A61K31/7052 , A61K38/00 , A61K38/05 , A61K38/21 , A61K38/55 , A61K45/00 , A61P1/16 , A61P31/12 , A61P31/14 , A61P43/00 , C07C205/51 , C07C229/00 , C07D209/02 , C07K5/02 , C07K5/103 , C07K7/02 , C07K7/04
CPC分类号： C07K7/06 , A61K31/16 , A61K31/195 , A61K31/27 , A61K31/357 , A61K31/385 , A61K31/403 , A61K31/4164 , A61K31/445 , A61K38/05 , C07C205/51 , C07K5/101 , C07K7/02 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide a new peptide compound having HCV protease inhibition activity and a method for producing the compound, in addition, a pharmaceutical composition containing the compound and a method for using them in treating diseases associated with HCV proteases. SOLUTION: A new class of HCV protease inhibitors, a pharmaceutical composition containing one or more kinds of the compounds, a method for producing the pharmaceutical composition containing one or more kinds of the compounds, a method for treating, preventing or improving one or more symptoms of hepatitis C, a method for controlling the interaction between HCV polypeptides and HCV proteases, a compound inhibiting HCV NS3/NS4a serine protease activity and a peptide compound including an amino acid sequence from P3 to P2' are disclosed. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供具有HCV蛋白酶抑制活性的新型肽化合物及其制备方法，此外，含有该化合物的药物组合物及其用于治疗与HCV蛋白酶相关疾病的方法。解决方案：新一类HCV蛋白酶抑制剂，含有一种或多种化合物的药物组合物，含有一种或多种化合物的药物组合物的制备方法，治疗，预防或改善一种或更多的丙型肝炎症状，控制HCV多肽和HCV蛋白酶之间相互作用的方法，抑制HCV NS3 / NS4a丝氨酸蛋白酶活性的化合物和包含P3至P2'氨基酸序列的肽化合物。版权所有（C）2010，JPO＆INPIT

6. 发明专利

JP2009051860A New peptide as ns3-serine protease inhibitor of hepatitis c virus 审中-公开
标题翻译：新型肽作为丙型肝炎病毒的NS3-丝氨酸蛋白酶抑制剂
公开(公告)号：JP2009051860A
公开(公告)日：2009-03-12
申请号：JP2008275159
申请日：2008-10-27
申请人： Dendreon Corp , Schering Corp , シェーリングコーポレイションSchering Corporation , デンドレオンコーポレイション
发明人： SAKSENA ANIL K , GIRIJAVALLABHAN VIYYOOR MOOPIL , LOVEY RAYMOND G , JAO EDWIN E , BENNETT FRANK , MCCORMICK JINPING L , WANG HAIYAN , PIKE RUSSELL E , BOGEN STEPHANE L , CHAN TIN-YAU , LIU YI-TSUNG , ZHU ZHAONING , NJOROGE F GEORGE , ARASAPPAN ASHOK , PAREKH TEJAL N , GANGULY ASHIT K , CHEN KEVIN X , VENKATRAMAN SRIKANTH , VACCARO HENRY A , PINTO PATRICK A , SANTHANAM BAMA , WU WANLI , SISKA HENDRATA , HUANG YUHUA , SCOTT JEFFREY KEMP , ODILE ESTHER LEVY , LIM-WILBY MARGUERITA , TAMURA SUSAN Y
IPC分类号： A61K45/00 , C07K14/81 , A61K31/7052 , A61K31/7056 , A61K38/00 , A61K38/21 , A61K38/55 , A61P1/16 , A61P31/12 , A61P31/14 , A61P43/00 , C07K5/02 , C07K5/062 , C07K5/065 , C07K5/08 , C07K5/087 , C07K7/02
CPC分类号： C07K5/0202 , A61K38/00 , C07K5/0812 , C07K5/0827 , C07K7/02
摘要： PROBLEM TO BE SOLVED: To provide a novel hepatitis C virus (HCV) protease inhibitor, a pharmaceutical composition comprising at least one such inhibitor, a production method of the inhibitor and a method of using the inhibitor for treating hepatitis C and disorders associated therewith. SOLUTION: A new peptide compound is useful as an HCV NS3/NS4a serine protease inhibitor. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供一种新型丙型肝炎病毒（HCV）蛋白酶抑制剂，包含至少一种这样的抑制剂的药物组合物，抑制剂的制备方法和使用该抑制剂治疗丙型肝炎和病症的方法相关联。解决方案：新的肽化合物可用作HCV NS3 / NS4a丝氨酸蛋白酶抑制剂。版权所有（C）2009，JPO＆INPIT

8. 发明专利

ES2317900T3 INHIBIDORES DE SERINA PROTEASA NS3 MACROCICLICOS DEL VIRUS DE LA HEPATITIS C QUE COMPRENDEN FRAGMENTOS N-CICLICAS P2. 未知
公开(公告)号：ES2317900T3
公开(公告)日：2009-05-01
申请号：ES01926601
申请日：2001-04-03
申请人： SCHERING CORP
发明人： CHEN KEVIN X , ARASAPPAN ASHOK , VENKATRAMAN SRIKANTH , PAREKH TEJAL N , GU HAINING , NJOROGE F GEORGE
IPC分类号： C07K7/06 , C12N9/99 , A61K31/7052 , A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/08 , A61K38/21 , A61K38/55 , A61K45/00 , A61P31/12 , A61P31/14 , A61P43/00 , C07K1/02 , C07K5/023 , C07K5/062 , C07K5/065 , C07K5/08 , C07K5/083 , C07K5/087 , C07K5/107 , C07K5/12 , C07K7/02 , C07K14/18
摘要： Un compuesto macrocíclico, incluyendo enantiómeros; estereoisómeros, rotámeros y tautómeros de dicho compuesto, y las sales o solvatos farmacéuticamente aceptables de dicho compuesto, teniendo dicho compuesto la estructura general mostrada en la Fórmula I: ** ver fórmula** donde: X e Y se seleccionan independientemente entre los radicales: alquilo, alquil-arilo, heteroalquilo, heteroarilo, arilheteroarilo, alquil-heteroarilo, cicloalquilo, éter alquílico, éter alquil-arílico, éter arílico, alquilamino, arilamino, alquil-arilamino, alquilsulfuro, alquilarilsulfuro, arilsulfuro, alquilsulfona, alquilarilsulfona, arilsulfona, alquil-alquilsulfóxido, alquil-arilsulfóxido, alquil-amida, alquil-arilamida, arilamida, alquilsulfonamida, alquil-arilsulfonamida, arilsulfonamida, alquilurea, alquil-arilurea, arilurea, alquilcarbamato, alquil-arilcarbamato, arilcarbamato, alquil-hidrazida, alquil-arilhidrazida, alquilhidroxamida, alquil-arilhidroxamida, alquilsulfonilo, arilsulfonilo, heteroalquilsulfonilo, heteroarilsulfonilo, alquil-carbonilo, arilcarbonilo, heteroalquilcarbonilo, heteroarilcarbonilo, alcoxi-carbonilo, ariloxi-carbonilo, heteroariloxicarbonilo, alquilamino-carbonilo, arilaminocarbonilo, heteroaril-aminocarbonilo o una combinación de los mismos, con la condición de que X e Y pueden estar opcionalmente sustituidos adicionalmente con radicales seleccionados del grupo que consiste en aromático, alquilo, alquilarilo, heteroalquilo, aril-heteroarilo, alquil-heteroarilo, cicloalquilo, éter alquílico, éter alquil-arílico, alquilsulfuro, alquilarilsulfuro, alquilsulfona, alquilarilsulfona, alquilamida, alquil-arilamida, alquilsulfonamida, alquilaminas, alquil-arilaminas, alquil-arilsulfonamida, alquilurea, alquil-arilurea, alquilcarbamato y alquil-arilcarbamato; R 1 = COR 5 o B(OR)2, donde R 5 = H, OH, OR 8 , NR 9 R 10 , CF3, C2F5, C3F7, CF2R 6 , R 6 , COR 7 donde R 7 = H, OH, OR 8 , CHR 9 R 10 , o NR 9 R 10 , donde R 6 , R 8 , R 9 y R 10 se seleccionan independientemente del grupo que consiste en H, alquilo, arilo, heteroalquilo, heteroarilo, cicloalquilo, cicloalquilo, arilalquilo, heteroarilalquilo, CH (R1'' )COOR11 , CH(R1'' )CONR12R13 , CH(R1'' )CONHCH(R2'' )COOR11 , CH(R1'' )CONHCH(R2 )CONR12R13 , CH(R1'' ) CONHCH(R2'' )R'', CH(R1'' )CONHCH(R2'' )CONHCH(R3'' )COOR11 , CH(R1'' )CONHCH(R2'' )CONHCH(R3'' ) CONR12R13 , CH(R1'' )CONHCH(R2'' )CONHCH(R3'' )CONHCH(R4'' )COOR11 , CH(R1'' )CONHCH(R2'' )CONHCH (R3'' )CONHCH(R4'' )CONR12R13 , CH(R1'' )CONHCH(R2'' )CONHCH(R3'' )CONHCH(R4'' )CONHCH(R5'' )-COOR11 , H(R1'' )CONHCH(R2'' )CONHCH(R3'' )CONHCH(R4'' )CONHCH-(R5'' ) CONR12R13 , donde R1'' , R2'' , R3'' , R4'' , R5'' , R 11 , R 12 , R 13 , y R'''' se seleccionan independientemente entre un grupo que consiste en H, alquilo, arilo, heteroalquilo, heteroarilo, cicloalquilo, alquil-arilo, alquil-heteroarilo, aril-alquilo y heteroaralquilo; Z se selecciona entre O, N, o CH; W puede estar presente o ausente, y si W está presente, W se selecciona entre C=O, C=S, o SO 2; Q puede estar presente o ausente, y cuando Q está presente, Q es CH, N, P, (CH2)p, (CHR)p, (CRR'')p, O, NR, S, o SO 2; y cuando Q está ausente, M también está ausente, y A está unido directamente a X; A es O, CH 2, (CHR) p, (CHR-CHR'') p, (CRR'') p, NR, S, SO 2 o un enlace; E es CH, N o CR, o un enlace doble hacia A, L o G; G puede estar presente o ausente, y cuando G está presente, G es (CH 2) p, (CHR) p, o (CRR'') p,; y cuando G está ausente, J está presente y E está conectado directamente al átomo de carbono donde también se conectó G; J puede estar ausente o presente, y cuando J está presente, J es (CH 2) p, (CHR) p, o (CRR'') p, SO 2, NH, NR o O; y cuando J está ausente, G está presente y E está conectado directamente a N; L puede estar presente o ausente, y cuando L está presente, L es CH, CR, O, S o NR; y cuando L está ausente, M puede estar ausente o presente, y si M está presente estándo ausente L, M está unido directamente e independientemente a E, y J está unido directamente e independientemente a E; M puede estar presente o ausente, y cuando M está presente, M es O, NR, S, SO2, (CH2)p, (CHR)p (CHR-CHR'')p, o (CRR'')p; p es un número de 0 a 6; y R, R'', R 2 , R 3 y R 4 se seleccionan independientemente del grupo que consiste en H; alquilo C1-C10; alquenilo C 2-C 10; cicloalquilo C 3-C 8; heterocicloalquilo C 3-C 8, alcoxi, ariloxi, alquiltio, ariltio, amino, amido, éster, ácido carboxílico, carbamato, urea, cetona, aldehído, ciano, nitro; átomos de oxígeno, nitrógeno, azufre, o fósforo numerándose dichos átomos de oxígeno, nitrógeno, azufre, o fósforo de cero a seis; (cicloalquil)alquilo y (heterocicloalquil)alquilo, donde dicho cicloalquilo está formado por tres a ocho átomos de carbono, y cero a seis átomos de oxígeno, nitrógeno, azufre, o fósforo átomos, y dicho alquilo tiene de uno a seis átomos de carbono; arilo; heteroarilo; alquil-arilo; y alquil-heteroarilo; pudiendo estar sustituidos opcionalmente dichos radicales alquilo, heteroalquilo, alquenilo, heteroalquenilo, arilo, heteroarilo, cicloalquilo y heterocicloalquilo, refiriéndose dicho término "sustituido" a la sustitución opcional y adecuada con uno o más radicales seleccionados del grupo que consiste en alquilo, alquenilo, alquinilo, arilo, aralquilo, cicloalquilo, heterocíclico, halógeno, hidroxi, tio, alcoxi, ariloxi, alquiltio, ariltio, amino, amido, éster, ácido carboxílico, carbamato, urea, cetona, aldehído, ciano, nitro, sulfonamida, sulfóxido, sulfona, sulfonilurea, hidrazida, e hidroxamato.

9. 发明专利

PL359359A1 MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES 未知
公开(公告)号：PL359359A1
公开(公告)日：2004-08-23
申请号：PL35935901
申请日：2001-04-03
申请人： SCHERING CORP
发明人： CHEN KEVIN X , ARASAPPAN ASHOK , VENKATRAMAN SRIKANTH , PAREKH TEJAL N , GU HAINING , NJOROGE F GEORGE , GIRIJAVALLABHAN VIYYOOR M , GANGULY ASHIT , SAKSENA ANIL , JAO EDWIN , YAO NANHUA H , PRONGAY ANDREW J , MADISON VINCENT S , VIBULBHAN BANCHA
IPC分类号： A61K31/7052 , A61K38/00 , C12N9/99 , A61K38/08 , A61K38/21 , A61K38/55 , A61K45/00 , A61P31/12 , A61P31/14 , A61P43/00 , C07K1/02 , C07K5/023 , C07K5/08 , C07K5/083 , C07K5/12 , C07K7/02 , C07D498/00 , C07K7/06
摘要： The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such macrocycles as well as methods of using them to treat disorders associated with the HCV protease.

10. 发明专利

CZ20023321A3 Macrocyclic compound and pharmaceutical preparation 未知
公开(公告)号：CZ20023321A3
公开(公告)日：2003-01-15
申请号：CZ20023321
申请日：2001-04-03
申请人： SCHERING CORP
发明人： CHEN KEVIN X , ARASAPPAN ASHOK , VENKATRAMAN SRIKANTH , PAREKH TEJAL N , GU HAINING , NJOROGE F GEORGE , GIRIJAVALLABHAN VIYYOOR M , GANGULY ASHIT , SAKSENA ANIL , JAO EDWIN , YAO NANHUA H , PRONGAY ANDREW J , MADISON VINCENT S , VIBULBHAN BANCHA
IPC分类号： C12N9/99 , A61K31/7052 , A61K38/00 , A61K38/08 , A61K38/21 , A61K38/55 , A61K45/00 , A61P31/12 , A61P31/14 , A61P43/00 , C07K1/02 , C07K5/023 , C07K5/08 , C07K5/083 , C07K5/12 , C07K7/02 , C07D498/12 , C07K7/06
摘要： The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such macrocycles as well as methods of using them to treat disorders associated with the HCV protease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式